Monthly information on share capital and company voting

PARIS, April 07, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
03/31/2026	100,590,994	106,001,228

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

Attachments

Voting_Rights_PR_March_2026_EN

Recommended Reading

March 19, 2026 19:21 ET | Source: Cellectis Inc.

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became...
Read More
March 12, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Read More

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

Tags

Attachments

Recommended Reading